Management of venous thromboembolism in pregnancy

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 15, Issue 4, 2001, Pages 583-603

  Greer, I A ^a   Thomson, A J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Heparin; Low molecular weight heparin; Pregnancy; Thrombophilia; Thrombosis; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; COUMARIN; DALTEPARIN; DANAPAROID; DEXTRAN; ENOXAPARIN; FIBRINOLYTIC AGENT; HEPARIN; HEPARINOID; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; THROMBIN INHIBITOR; TINZAPARIN; WARFARIN;

ALLERGY; ANAPHYLAXIS; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DELIVERY; DOSE RESPONSE; DRUG EFFICACY; DRUG ELIMINATION; DRUG MILK LEVEL; DRUG SAFETY; DRUG USE; HUMAN; LABOR; LUNG EMBOLISM; MAINTENANCE THERAPY; MATERNAL MORBIDITY; MATERNAL MORTALITY; META ANALYSIS; OSTEOPOROSIS; PATHOGENESIS; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TERATOGENICITY; THROMBOCYTOPENIA; THROMBOPHILIA; TREATMENT OUTCOME; UNITED KINGDOM; VEIN THROMBOSIS;

EID: 0034879238     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1053/beog.2001.0202     Document Type: Article

References (82)

1. Venous thromboembolic disease in obstetrics and gynaecology: The Scottish experience
2. Thromboembolic disease associated with pregnancy: An 11 year review
3. Risk factors for pregnancy-associated venous thromboembolism
4. Prevalence of the post-thrombotic syndrome in young women with previous venous thromboembolism
5. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy
6. Haemostasis and thrombosis in pregnancy
7. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy
8. Late venous function in the leg after deep venous thrombosis occurring in relation to pregnancy
9. Hyperhomocysteinemia as a risk factor for deep vein thrombosis
10. The challenge of thrombophilia in maternal-fetal medicine
11. Prothrombin and factor V mutations in women with thrombosis during pregnancy and the puerperium
12. Prothrombin 20210GA, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy
13. Congenital thrombophilia
14. Resistance to activated protein C due to a Factor V gene mutation: The most common inherited risk factor of thrombosis
15. A common genetic variation in the three untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
16. A mutation in the prothrombin gene contributing to venous thrombosis in pregnancy
17. Thrombosis in pregnancy: Maternal and fetal issues
18. Venous thrombosis: A multicausal disease
19. Thrombosis in pregnancy and congenital deficiencies in AT III, Protein C or Protein S: Study of 78 women
20. Thrombotic risk in hereditary anti-thrombin III, protein C or protein S deficiency
21. Thrombosis during pregnancy and surgery in patients with congenital deficiency of anti-thrombin III, protein C-protein S
22. Arg 506-Gln mutation in Factor V and risk of thrombosis during pregnancy
23. Sixth ACCP consensus conference on antithrombotic therapy. Use of antithrombotic agents during pregnancy
24. Low risk of recurrent thromboembolism in pregnancy
25. The risk of antenatal subcutaneous heparin prophylaxis: A controlled trial
26. Recurrent venous thromboembolic disease and use of oral contraceptives
27. Recurrent thromboembolism in pregnancy and puerperium: Is there a need for thromboprophylaxis?
28. For the recurrence of clot in this pregnancy (ROCIT) study group. Safety of withholding antepartum heparin in women with a previous episode of venous thromboembolism
29. Serial IPG in pregnancy patients with clinically suspected DVT. Clinical validity of negative findings
30. Diagnostic efficacy of IPG in suspected venous thrombosis: An alternative to venography
31. Detection of DVT by realtime B-mode ultrasonography
32. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED)
33. Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism
34. Diagnosis of deep venous thrombosis and pulmonary embolism
35. Diagnostic tests for deep vein thrombosis. Clinical usefulness depends on probability of disease
36. Value of assessment of pretest probability of deep-vein thrombosis in clinical management
37. Non-haemorrhagic obstetric shock
38. Risks to the fetus of radiological procedures used in the diagnosis of maternal venous thromboembolic disease
39. Factor V Leiden paradox: Risk of deep-vein thrombosis but not of pulmonary embolism
40. Anticoagulants in pregnancy: Fetal defects
41. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves
42. Peripartum prophylaxis of thromboembolism
43. Placental transport of heparin
44. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy: Study by direct fetal blood sampling under ultrasound
45. Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy
46. Safety of low-molecular-weight heparin in pregnancy: A systematic review
47. Hazards of heparin: Allergy, heparin-induced thrombocytopenia and osteoporosis
48. Thrombocytopenia antithrombin deficiency and extensive thromboembolism in pregnancy - Treatment with low molecular weight heparin
49. Heparin induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin
50. Low-molecular-weight heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one women at high risk
51. Epidemiology, risk factors and prophylaxis of venous thrombo-embolism in obstetrics and gynaecology
52. Antifactor XA profiles in pregnant women receiving antenatal thromboprophylaxis with enoxaparin for prevention and treatment of thromboembolism in pregnancy
53. Thromboprophylaxis with low-molecular-weight heparin `dalteparin' in pregnancy
54. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies
55. Thromboprophylaxis with low molecular mass heparin, `Fragmin' (dalteprin), during pregnancy - Longitudinal safety study
56. Fetal risks with dextran during delivery
57. Technical note: Compression stockings and posture - A comparative study of their effects on the proximal deep veins in the leg at rest
58. Hirudin treatment in a breastfeeding woman
59. Prevention of venous thromboembolism
60. CLASP: A randomised trial of low dose aspirin for the prevention and treatment of pre-eclampsia among 9,364 pregnant women
61. A meta-analysis of low-dose aspirin for prevention of pregnancy-induced hypertensive disease
62. Heparin
63. Anticoagulant drugs in the treatment of pulmonary embolism: A controlled trial
64. Heparin in the treatment of pulmonary thromboembolism
65. The clinical course of pulmonary embolism
66. Antithrombotic therapy for venous thromboembolic disease
67. Low molecular weight heparin in the treatment of venous thromboembolism: An updated meta-analysis
68. Low molecular weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials
69. A comparison of low-molecular weight heparin with unfractionated heparin for acute pulmonary embolism
70. Low molecular weight heparin for the immediate management of thromboembolic disease in pregnancy
71. Treatment of venous thromboembolism
72. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
73. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep venous thrombosis. A meta-analysis
74. A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy
75. Changes in the pharmacokinetics of the low molecular weight heparin enoxaparin sodium during pregnancy
76. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaran (Org 10172)
77. Long-term treatment of venous thromboembolism: The place of low molecular weight heparin
78. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis
79. Guidelines on oral anticoagulation: Third edition
80. Central nerve block and thromboprophylaxis - Is there a problem?
81. Spinal and epidural blockade and perioperative low molecular weight heparin: Smooth sailing on the Titanic